

Date of Preparation: February 17, 2006

John M. Flack, M.D., M.P.H.

CURRICULUM VITAE
JOHN M. FLACK, M.D., M.P.H., F.A.H.A.

**Clinical
Research
Center:** Wayne State University
Clinical Research Center
Department of Internal Medicine
4160 John R. Ste 1002
Detroit, Michigan 48201

Office: University Health Center
Suite 2E
Department of Internal Medicine
4201 St. Antoine
Detroit, Michigan 48201

Telephone:

E-mail:

EDUCATION:

- 1990 M.P.H., (Epidemiology) University of Minnesota School of Public Health, Minneapolis, MN
- 1988-90 Postdoctoral Research Fellow, (Cardiovascular Epidemiology) National Heart Lung and Blood Institute (NHLBI), Division of Epidemiology, University of Minnesota School of Public Health Minneapolis, MN
- 1986-88 M.P.H., Program University of Oklahoma School of Public Health, Oklahoma City, OK
- 1987 Fellow, 13th U.S. Ten-day Seminar on the Epidemiology and Prevention of Cardiovascular Diseases, Sponsored by the American Heart Association, Lake Tahoe, CA
- 1985-86 Chief Medical Resident, Department of Medicine, University of Oklahoma Health Sciences, Oklahoma City, OK
- 1982-85 Internship/Residency, University of Oklahoma Health Sciences Center, Oklahoma Memorial Hospital, Oklahoma City, OK
- 1982 M. D., University of Oklahoma School of Medicine, Oklahoma City, OK.
- 1978 B.S., Chemistry (Math Minor) Langston University, Langston, OK

RESEARCH INTERESTS:

- 1) Clinical trial design, implementation, and monitoring

John M. Flack, M.D., M.P.H.

- 2) Hypertension in African-Americans, and the influence of the renin-angiotensin-aldosterone-kinin system on mediating salt-sensitivity and target organ damage; and
- 3) The development and implementation of information systems and clinical decision support systems to measure, monitor, and improve the quality of medical care, particularly in the area of cardiovascular-renal diseases

FACULTY APPOINTMENTS:

- 2005-Present Interim Chairman Department of Internal Medicine, Wayne State University School of Medicine
- 2000-2005 Associate Chairman for Academic Affairs and Chief Quality Officer, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI
- 1999-00 Associate Chairman for Clinical Research and Urban Health Outcomes, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI
- 1999-2003 Graduate Faculty Appointment, Professor, Department of Community Medicine
- 1997-98 Associate Chairman, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI
- 1997-Present Professor, Departments of Internal Medicine and Community Medicine, Wayne State University School of Medicine
- 1994-97 Associate Professor of Surgery, Medicine and Public Health Sciences, Bowman Gray School of Medicine, Winston Salem, NC
- 1994 Associate Professor, Division of General and Preventive Medicine, University of Minnesota School of Medicine, Minneapolis, MN
- 1992-94 Assistant Professor, Division of General and Preventive Medicine, University of Minnesota School of Medicine
- 1990-92 Assistant Professor, School of Public Health, Division of Epidemiology, University of Minnesota
- 1986-88 Instructor of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK

HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS:

- 2005 Specialist in Chief for Internal Medicine, Detroit Medical Center, Detroit, MI
- 2005 Medical Executive Committee, Detroit Medical Center, Detroit, MI
- 2005 Executive Management Team, Detroit Medical Center, Detroit, MI

John M. Flack, M.D., M.P.H.

- 2005 Harper University Hospital Leadership Team, Detroit Medical Center, Detroit, MI
- 2005 Cardiac & Vascular Institute Steering Committee, Detroit Medical Center, Detroit, MI
- 2004 Consultant, John D. Dingell Veterans Affairs Medical Center, Detroit, MI
- 1998-99 Chief of Medicine, Detroit Medical Center, Central Region Hospitals, Detroit, MI
- 1998-99 Acting Director, Division of General Medicine, Wayne State University School of Medicine
- 1998-00 Vice President, Vencor Hospital, Detroit/Metro-Medical Staff, Detroit, MI
- 1997-Present Director, Cardiovascular Epidemiology and Clinical Applications (CECA) Program, Department of Internal Medicine, Wayne State University School of Medicine
- 1994-97 Associate Director and Medical Director, Hypertension Center, Bowman Gray School of Medicine
- 1992-94 Director, Division of General and Preventive Medicine, University of Minnesota, Minneapolis, MN
- 1992 Co-Director, Division of General Medicine, University of Minnesota. Minneapolis, MN
- 1990-91 Deputy Director, Institute of Preventive Cardiology and Medicine, Metropolitan Mount Sinai Medical Center, Phillips Campus, Minneapolis, MN
- 1990-91 Medical Staff, Abbott-Northwestern Hospital, Minneapolis, MN
- 1989-91 Medical/Emergency Room Staff, Metropolitan Mount Sinai Medical Center, Minneapolis, MN
- 1989-91 Consultant, Quality Quest Inc., Minneapolis, MN
- 1989-91 Consultant, United Healthcare Corp., Minneapolis, MN
- 1986-88 Associate Director, Hypertension Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 1986-88 Director, General Medicine Consult Service, University of Oklahoma Health Sciences Center
- 1977-78 _____
- 1976 _____

MEMBERSHIP SOCIETIES:

Sigma Pi Phi Fraternity
Alpha Omega Alpha (AOA) Medical Honor Society
American College of Physicians

Association of Professors of Medicine
Association of Black Cardiologists (ABC), Chair of CVD Epidemiology Subcommittee
Faculty of 1000 in Medicine
International Society on Hypertension in Blacks (ISHIB), Immediate Past President
National Medical Association (NMA)
Michigan Medical Society
American Heart Association Council for High Blood Pressure Research
American College of Cardiology

LICENSURE AND BOARD CERTIFICATION:

1999-09 Specialist in Clinical Hypertension, American Society of Hypertension
1997 Michigan (Active)
1994 North Carolina (Inactive)
1990 Basic Rescuer, American Heart Association
1990 Advanced Cardiac Life Support Provider, American Heart Association
1988 Minnesota (Inactive)
1985 Diplomate, American Board of Internal Medicine
1983 Diplomate, National Board of Medical Examiners
1982 Oklahoma (Inactive)

HONORS/AWARDS:

2005 *Crain's Detroit Business* Health Care Hero Award for Outstanding Physician Achievement
2005 Awarded Pillar Award of Excellence for Reducing Health Disparities, Michigan Peer Review Organization
2004 Who's Who Among Executives and Professional in Healthcare
2004 Distinguished "Alumnus" Award, Langston University-outstanding accomplishments in the field of medicine and serving as speaker for honors convocation
2004 Distinguished "Alfred Deutsch" Award WSU-Dept of OBGYN
2003 Selected as one of the "Best Doctors in America"
2003 Distinguished Service Award of the National Kidney Foundation, Inc.
2003 Attending of the Month of March, WSU-Dept of Med Harper University Hospital
2002 Selected as one of the "Best Doctors in America"
2001 Fellow of the American Heart Association (F.A.H.A.)
2001 Department of Internal Medicine Wayne State University College Teaching Award
2001 Life-term Member of The National Registry of Who's Who. Published 2002 ed.
1998 Selected as one of the "Best Doctors in America," Woodward/White, Inc.
1998 Dr. Daniel D. Savage Memorial Scientific Award, Association of Black Cardiologists

1995
1995

1994 Selected as Faculty for Bush Faculty Development Program in Excellence and Diversity in Teaching, University of Minnesota-Twin Cities
1993 Distinguished Research Award, International Society on Hypertension in Blacks

1993
1992
1992

John M. Flack, M.D., M.P.H.

| | |
|---------|--|
| 1991 | |
| 1988-90 | Higher Ability Minority Scholarship, University of Minnesota School of Public Health |
| 1988 | Special Recognition Award, University of Oklahoma Health Sciences Center, Student National Medical Association |
| 1988 | |
| 1985 | Award of Academic Excellence, VA Medical Center, Afro-American Program |
| 1982 | |

AD HOC:

| | |
|--------------|--|
| 2005 | Reviewer, NCMHD Centers of Excellence in Partnership for Community Outreach, Research on Health Disparities and Training (Project EXPORT - Establishing Exploratory Centers) |
| 2005 | Member, NIH (NIEHS) High Profile Review Clinical Research Support Services |
| 2005 | Chair, Hypertension Expert Working Group (NKF of Michigan) |
| 2005 | Member, Research Review Committee Department of Internal Medicine |
| 2005 | Member, WSU Research Advisory Committee |
| 2005 | Member, WSU Population Sciences Panel |
| 2005 | Member, WSU Hematology Oncology Academic Search Committee |
| 2005 | Member, Tarka Specialty Consultants Steering Committee |
| 2005 | Chair, CUAAH Health Disparities Committee |
| 2004 | Member, DMC Medical Staff, Informal Investigation Committee |
| 2004 | Member, Council for the Advancement of Diabetes Research & Education (CADRE) |
| 2004 | Member, Preventive Cardiology Junior Faculty Awards Steering Committee (Pfizer, Inc.) |
| 2004-05 | Member, Wayne County Delegate (Wayne County Med Society of Southeast MI) |
| 2004 | Reviewer, National Health and Medical Research Council (Australia) |
| 2004 | Member, National Kidney Disease Education Program Committee (NKDEP) |
| 2004 | Member, WSU Hutzel Women's Hospital, Disciplinary Investigation Committee |
| 2004 | Member, NIH National Heart Lung and Blood Institute Sub-clinical Cardiovascular Disease Working Group |
| 2003 | Member, Metro Detroit Health Care Disparities Task Force (HFH) |
| 2003 | Reviewer, National Institute of Diabetes & Digestive & Kidney Disease |
| 2003-05 | Member, WSU INPHASE (Institutes for Population Studies Health Assessment, Administration, Services and Economics) |
| 2002 | Member, Steering Committee, National Kidney Disease Ed Program |
| 2002-04 | Member, Epidemiology and Clinical Trials Center (EpiCenter), ABC |
| 2002 | Member, Program Committee Clinical Nephrology Meeting 2002 (NKF) |
| 2002 | Member, Worldwide Advisory Board |
| 2001 | Member, American Heart Association's Scientific Committee Session 2001 |
| 2001-Present | Consultant, Center for Disease Control (WISEWOMAN) Well-Integrated Screening and Evaluation for Women Across the Nation |
| 2001 | Member, Affiliated Internist's Data Analysis Committee |
| 2001 | Member, Affiliated Internist's Ambulatory Steering Committee |
| 2001 | Member, Affiliated Internist's Informatics Committee |
| 2001 | Member, Affiliated Internist's Quality Improvement/Chronic Disease Management Committee |
| 2001 | Member, National Institute of Dental and Craniofacial Research-Special Emphasis Panel |
| 2001 | Member, American Heart Association, Metropolitan Detroit Board of Directors |

John M. Flack, M.D., M.P.H.

- 2001 Co-Chair, Upcoming "Sixth Congress on the Treatment of Cardiovascular Disease in African-Americans", (Speaker and Session Moderator).
- 2001 Chair, (NIH) National Institutes of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis, Panel Review Group.
- 2001 Member, Medical and Scientific Advisory Board (MSAB), National Kidney Foundation
- 2000 Member, Michigan Peer Review Organization (MPRO), Board of Directors
- 2000-02 Member, Association of Professors of Medicine, Departmental Finance and Management Committee, Washington, DC
- 2000 Member, Mott Center, Advisory Committee, Wayne State University and DMC-Detroit, Michigan
- 2000 Chairman, Cardiovascular Risk Factor: New Challenges, New Opportunities Part I: Angiotensin-II & Cardiovascular Risk, American College of Cardiology, (ACC) Anaheim, CA
- 1999 Member, PSO Contracting & Reimbursement Work Group and Managed Care Contract Review Committee, DMC, Detroit, Michigan
- 1998 Scientific Program Chairman, Third Annual Congress on the Treatment of Cardiovascular Diseases in African-Americans, Dallas, TX
- 1998 Reviewer, Abstracts for ACC 48th Annual Scientific Session, Dallas, TX
- 1998 Reviewer, K23 and K24 Grant Awards, NHLBI
- 1997 Reviewer in Reserve, Agency for Health Care Policy
- 1997 Reviewer, Abstracts for American College of Cardiology (ACC) 47th Annual Scientific Session, Bethesda, MD
- 1997 Chairman, Expert Panel on Optimal Target-Organ Protection and Survival in African-Americans, Orlando, FL
- 1997 Scientific Program Chairman, Second Annual Congress on the Treatment of Cardiovascular Diseases in African-Americans, Orlando, FL
- 1997 Reviewer, "Clinical Trials Unit", NIDDK, U01 DK54047-01
- 1996 Grant Reviewer, Agency for Health Care Policy Research, Office of Scientific Affairs, Rockville, MD
- 1994 Member of Writing Group, National High Blood Pressure Education Program Working Group on Hypertension and Renal Disease
- 1992 Reviewer, "The Biology of Kidney Disease and Hypertension in Blacks", RFA DK/92-11
- 1991 Member, Writing Group to Revise American Heart Association Recommendations for Human Blood Pressure Determination by Sphygmomanometers
- 1991 Reviewer, NIH Small Grants Program (R03)
- 1991 Behavioral Science, Epidemiology and Prevention Study, American Heart Association
- 1990 Reviewer, NHLBI Bogalusa Heart Study, New Orleans

STUDY SECTIONS:

- 1999-2001 Steering Committee, OPERA Study, (International)
- 1999 Nebraska Department of Health and Human Services Cancer and Smoking Disease Research Program
- 1998-2002 Member, Agency for Health Care Policy Research (AHCPH), Health Care Quality and Effectiveness Research (HCQER) Study Section
- 1992-96 Member, Research Centers in Minority Institutions (RCMI) Review Committee, National Institutes of Health

PROFESSIONAL SERVICE:

- 2005 Chair, Morehouse School of Medicine, Clinical Research External Advisory Committee

John M. Flack, M.D., M.P.H.

- 2005 Member, National Kidney Foundation, Hypertension Expert Group
- 2005 Member, Association of Professors of Medicine (APM)
- 2005 Member, Association of Professors of Medicine (APM) Diversity Subcommittee
- 2005 Member, Michigan Peer Review Organization (MPRO)
- 2005 Member, Metro Detroit American Heart Association
- 2005 Member, High Blood Pressure Council of the American Heart Association
- 2005 Member, International Society on Hypertension in Blacks, (ISHIB)
- 2004 Member, Wayne County Medical Society Southeastern Michigan, Nomination and Election Committee
- 2004 Member, American Society of Hypertension, Inc, Board of Directors, Midwest Regional Chapter
- 2004 Immediate Past President, International Society on Hypertension in Blacks (ISHIB)
- 2003 Member, Medical and Scientific Advisory Board, National Kidney Foundation of Michigan
- 2002 Member, University Physician Services, Board of Directors
- 2001-2003 President, International Society of Hypertension in Blacks (ISHIB)
- 2002 Member, Henderson Scholars Program-University of Oklahoma-Leadership Advisory Committee
- 2001 Member, Wayne County Medical Society, Membership Committee
- 2001-2003 Member, Medical and Scientific Advisory Board, National Kidney Foundation
- 2001 Honorary Member, Pathfinders, in Medicine Awards Committee
- 2001 Member, WSU Advisory Committee, Liborio Tranchida, MD, Endowed Chair Campaign, Detroit, MI
- 2001-2002 Member, DMC Managed Care Contract Review Committee, Detroit, MI
- 2001 Member, DMC Hutzel Women's Hospital Stages of Life Program Team", Detroit.
- 2001-2003 Ex-Officio, Member of National Kidney Foundation, Medical and Scientific Advisory Committee
- 2000-Present Chair, Affiliated Internist Investment Committee, Detroit, MI
- 2000-2001 Board of Directors, Member, United Medical Management Co., Inc., Detroit, MI
- 1999-present Chair, DMC Central Region Credentialing Committee
- 1998-2000 Reviewer, Harper Hospital Medical Staff, Department of Medicine, Seed Grants
- 2000 Abstracter Grader, Annual Scientific Session American College of Cardiology
- 1999 Abstract Grader, American College of Cardiology 49th Annual Scientific Session
- 1999 Member, Internal Review Committee for the Department of Emergency Medicine, Wayne State University School of Medicine (Chair of Administrative Review)
- 1998 Member, Senior Servicer Planning and Advisory Committee, Detroit Medical Center
- 1998 Member, PSO Contracting and Reimbursement Group, Detroit Medical Center
- 1998 Member, Pediatric Internal Review Committee, Wayne State University School of Medicine
- 1998-2003 Board Member, Consortium for Southeastern Hypertension Control (COSEHC), Wake Forest University Baptist Medical Center, Winston-Salem, NC
- 1996-Present Member, External Advisory Committee to the Interdisciplinary Cardiovascular Group of Morehouse School of Medicine
- 2002-Present Chair, Morehouse School of Medicine, Clinical Research External Advisory Committee
- 1996 (Special Government Employee), FDA, Center for Drug Evaluation and Research, Division of Metabolic and Endocrine Drug Products
- 1995-1998 Steering Committee, Breast Cancer Prevention Trial (BCPT)
- 1995-97 Protocol Committee General Clinical Research Center (GCRC), Bowman Gray School of Medicine
- 1995-97 Advisory Committee, General Clinical Research Center (GCRC), Bowman Gray School of Medicine
- 1995 National Kidney Foundation, Early Intervention & Prevention Task Force
- 1995-Present Board of Trustees, International Society on Hypertension in Blacks, Inc. (ISHIB)

John M. Flack, M.D., M.P.H.

- 1995-97 Clinical Research Practices Committee (GCRC), Bowman Gray Medical School
1995 Chairman, Personnel Committee, International Society on Hypertension in Blacks, Inc. (ISHIB)
- 1995 Finance and Audit Committee, International Society on Hypertension in Blacks, Inc. (ISHIB)
- 1995-1996 Membership Committee, American Society of Hypertension
1995-96 Chairman, Parke-Davis, Southeastern United States African American Initiative
1995-1997 Steering Committee, Breast Cancer Prevention Trial (BCPT)
1995-1997 Cardiovascular Committee, Breast Cancer Prevention Trial
1995 Bristol-Myers Squibb Diabetes Education Faculty
1993-94 Long-Range Strategy Planning Committee, Department of Medicine, University of Minnesota
- 1993-94 Chair, Primary Care Subcommittee of the Long-Range Strategy Planning Committee, Department of Medicine, University of Minnesota
- 1993-94 Professional Services Committee, University of Minnesota
1993-94 Advisory Council, HealthSpan Research
1993-94 Managed Care Task Group, University of Minnesota Clinical Associates
1993-94 Academic Affairs Faculty Working Group, University of Minnesota
- 1992-Present African-American Lipid and Cardiovascular Council (AALCC)
1992-93 Agenda Planning Committee, American Heart Association
1991-92 Who's Who Among Rising Young Americans
1991-94 Board Member, American Heart Association, Minnesota Affiliate
1991-Present The American Society of Hypertension
1990-91 Subcommittee, Epidemiology MPH Admissions, University of Minnesota School of Public Health
- 1990-Present Research Awards Committee, Division of Epidemiology, University of Minnesota School of Public Health
- 1988-Present Faculty Advisor, Student National Medical Association, University of Oklahoma College of Medicine Chapter
- 1987-88 Residency Advisory Committee, Department of Medicine, University of Oklahoma
1987-88 Seed Grant Review Committee, University of Oklahoma College of Medicine
1986-88 Quality Assurance Committee, Oklahoma Foundation for Peer Review
1986-88 Medical Records Committee, Oklahoma Memorial Hospital
1986-88 Medical College Admissions Board, University of Oklahoma College of Medicine
1986-87
-
- 1982-83 Long-Range Planning Committee, Oklahoma University Health Sciences Center
1981-82 Medical College Admissions Board, Oklahoma University Health Sciences Center

Editorial Boards:

- 2005-Present Current Hypertension Reviews
2003 Hypertension
2003 Internal Medicine/Cardiology News
1990-Present Journal of Ethnicity and Disease
1991-98 Obesity and Health
1992-94 Issues in Hypertension and Atherosclerosis
1992-95 Urban Health
1993-98 The ABC Digest of Urban Cardiology

Manuscript Reviewer:

Advanced Studies in Medicine (ASiM)
American Journal of Cardiovascular Drugs
American College of Cardiology (Abstract Grader)
American Journal of Epidemiology
American Journal of Hypertension
American Journal of Medicine
Archives of Internal Medicine
Circulation (Journal of the American Heart Association)
Diabetes Care
Diabetes Metabolism Research and Reviews
Expert Opinion on Pharmacotherapy
Future-Drugs Ltd
Hypertension
Journal of the American College of Cardiology (JACC)
Journal of the American Medical Association
Journal of Ethnicity and Disease
Journal of Ethnicity and Health
Journal of Laboratory and Clinical Medicine
Journal of Neurological Sciences
Journal of General Internal Medicine
Journal of Behavioral Medicine
Journal of Human Hypertension
Journal of Experimental Medicine
Journal of American Geriatric Society
Medical Care
Mayo Clinic Proceedings
Preventive Medicine
Public Health Association
Women's Health in Primary Care

Community Service:

2005 Owen Elementary Head Start Program-March Parent Meeting
"Preventing Hypertension, Heart Disease & Diabetes in our Children
with Proper Nutrition"
2005 Center for Urban and African American Health (CUAAH)
-Past President & Future of African American Research
2004 Center for Urban and African American Health (CUAAH)
-Annual Martha G. Scott Health Screening Fair
2004 Helping Educate African American and Latinos on research being conducted on
health disparities "Cutting Edge Newsletter" (*article written on CUAAH*)
2003- Mentoring Program WSU-School of Medicine
2003 Wayne County Community College "Combating Health Disparities" (lecture/panel)
2003 Wayne County Department of Health "Cardiovascular Drug Therapy Which Drug
for Which Patient" (lecture/discussion)
2002 WSU-CECA Program, "Health Screening Fair"
2001 Senator Raymond M. Murphy's African American Health Conference
2001 NIH National High School Students Summer Mentoring Research Program
2001
1994 Hennepin County Medical Society, "Success By 6" Program
1994

Teaching:

- 2005
- Wayne State University
Department of Family Medicine/Clinical Medicine Lecture
“What is Race? What is Ethnicity?”
- Wayne State University
Department of Family Medicine/Clinical Medicine Lecture
“An Approach to Understand Health Disparities”
- Wayne State University
Resident Summer Lecture Series
“Hypertensive Urgencies, Emergencies, and BP Management During Acute Stroke”
- Wayne State University Guest Lecturer, Community Medicine Students
“Cardiovascular Epidemiology: An Overview”
- In-patient ward rounding, February (Detroit Receiving Hospital)
- 2004
- Wayne State University
Dept of Medicine 2nd Asian American Conference
“What’s New in Hypertension?”
- DMC-Dept of Obstetrics & Gynecology (Sinai-Grace)
“Hypertension Therapeutics in Women: Special Issues”
- WSU-African American Student Society
“Unraveling Selected African American Health Disparities with a Multi-disciplinary Team”
- Wayne State University Department of Medicine
Endocrinology Grand Rounds
“Why Does Sodium Raise BP in Obese Persons”
Synergy Medical Covenant Healthcare
- Internal Medicine Grand Rounds
“Hypertension in Blacks”
- Wayne State University
Medical Alumni Association Conference
“Obesity/Hypertension”
- Wayne State University-Neurology Grand Rounds
“Management of BP in Acute Stroke, Hypertensive Emergencies and Urgencies”
- Wayne State University
Emergency Medicine Grand Rounds
“Management/Disposition of New Onset & Uncontrolled Hypertension in the Emergency Department”
- Wayne State University
Family Medicine Conference
“An Approach to Understand Health Disparities”
- Grady Memorial Hospital-Grand Rounds
“The Pervasive Metabolic & Hemodynamic Consequences of Obesity:

No Good News”

Wayne State University
Resident Summer Lecture Series
“Hypertension Update”

Wayne State University
Center for Urban and African American Health Lecture Series
“Obesity: The Pervasive Weapon of Mass Public Health Destruction”

Wayne State University Symposium
Michigan Consortium for Minority Health & Academic Development
“Racial & Ethnic Disparities: The looking glass into broader societal and health systems problems”

Wayne State University
American Medical Student Association Conference
“What are Healthcare Disparities”

WSU-University Internal Medicine Specialists
Employee In-service lecture and discussion
“Hypertension: The Silent Killer”

Wayne State University
Department of Family Medicine/Clinical Medicine
“Ethnic & Racial Disparities in Health Status”

2003

Wayne State University
Grand Rounds “Clinical Patient Care”
Grand Rounds “Hypertension Update”

General Motors Occupational Health symposium “What’s New in Hypertension?”
In-patient ward rounding, March (Harper Hospital)
Wayne State University-School of Medicine
Preventive Medicine in Public Health
“Ethnic Race Disparities in Health Status”

DMC-Sinai-Grace Hospital
“Hypertension Emergencies and Urgencies”

Wayne State University-School of Medicine
“Advanced Hypertension Management Course”

2002

Wayne State University-School of Medicine
Pathophysiology
Year II Medical Students
Clinical Research Center Lectures Series

Wayne State University-School of Medicine
2nd Annual Update in Internal Medicine - Bay Harbor
“Controversies and New Developments in High-Risk Hypertension: Focus on Diabetes Mellitus, Kidney Disease in AA

- In-patient ward rounding, March (Harper Hospital)
- National Kidney Foundation (NKF) Clinical Nephrology Lectures
- 2001 In-patient ward rounding, January (Harper Hospital)
- Wayne State University-Mini Medical School
“Living with Hypertension”
- Wayne State University-School of Medicine
Pathophysiology
Year II Medical Students
- Wayne State University-School of Medicine
Clinical Perspectives on Vascular Health
Year III Medical Students
- Wayne State University-School of Medicine
1st Annual Update in Internal Medicine - Bay Harbor, MI
“An Ounce of Prevention and a Pound of Cure”
- American Society of Hypertension (ASH)
Certified Specialist Exam-“Specialist in Clinical Hypertension”
- Wayne State University-School of Medicine
Preventive Medicine in Public Health
“Ethnic and Racial Disparities in Health Status
- 2000 In-patient ward rounding, April (Detroit Receiving Hospital) and June, (Harper Hospital)
- OSCE Exam
Third year students
Wayne State University- School of Medicine
- “Hypertensive, Urgencies, Emergencies, & Common Secondary Causes”
Cardiology Board Review Course
Wayne State University – School of Medicine
- “Diagnosis and Treatment of Hyperaldosteronism”
Endocrinology Review Course
Wayne State University- School of Medicine
- Supervise an Endocrinology fellow in clinic one-half day per week.
- 1999 “Peripheral Vascular Disease/HTN”
Board Review Course for Residents
Wayne State University- School of Medicine
- 1997 Seventh Annual Physician Assistant Satellite Comprehensive
Review Course “Hypertension Update.”
Wake Forest University School of Medicine

John M. Flack, M.D., M.P.H.

1996 Physician Assistant Program
Course on "Hypertension."
Wake Forest University School of Medicine

Radio/Television Appearance(s)

2005, WXYZ, "CVRx Surgical Procedure for Treatment of Hypertension", July 13, 2005 (*live taping*)

2005, CBS, Street Beat with Edward Foxworth, "The American Heart Association and its effect on African-Americans", January 31, 2005 (*live taping*)

2004, UPN/CBS "Hypertension in African Americans", October 11, 2004 (*live taping*)

2004, WLQV 1500 AM "Ask the Doctor" Live radio talk show, October 13, 2004

2004, The Dr. Jimmy Womack Show-WGPR 107.5 FM, "Hypertension"

2002, HealthQuest Live, hosted by the publisher of HealthQuest Magazine, Sara Lomax Reese, WURD 800 AM Philadelphia.

2001, The Dr. Jimmy Womack Show-WGPR 107.5 FM, "Hypertension", December 16, 2001

2001, Diane Watkins Show-WHPR 88.1 FM and TV 68, "Hypertension Unchecked Silences Hearts", [H.U.S.H.], May 25, 2001.

1999, Newspaper USA Today coverage of discovery that the Angiotensin converting Enzyme gene (II) polymorphism predicts salt-sensitivity in normotensive African-Americans, March 25.


1998, Network Television, Program on the weight loss drug Sibutramine, 48 Hours

Student and Resident Mentoring:


Research Residents:

| | | |
|------|--|--|
| 2005 | | |
| 2005 | | |
| 2005 | | |

John M. Flack, M.D., M.P.H.



2004-present Mentoring-Wayne State University School of Medicine student(s) classes of:



2003-present Mentoring-Wayne State University School of Medicine student(s) classes of:

2004-
2005-
2006-
2007-

2003

2003

2003

2003

2003

2002-present


2002

2002

2002

2002

2002



2001

2001

2001

2001

2001

2001-2002

2001

2000

2000

2000

2000

1998-2000

2000-present

1999-2002

1998

1999

GRANT APPLICATIONS PENDING

1. Cardiovascular and Behavioral Adjustments in Black Youth.

Role: Co-Investigator

To explore the effects of biobehavioral factors on cardiovascular functioning and psychosocial dysfunction in black youth.

GRANTS AND CONTRACTS SUPPORT (FUNDED)

1. Title: Center for Urban and African American Urban Health.
Funding: National Institute of Environmental Health Science [ES-012395]
Purpose: Understanding the mechanisms operating at multiple levels (environment, lifestyle, physiology, genetics) mediating known disparate chronic conditions and their precursors and to identify preventive strategies and therapeutic approaches that might alleviate the disproportionate burden of disease
Period: 09/01/2003 through 05/31/2008
Role: Principal Investigator
FTE: 25 %
 - Principal Investigator Administrative Core
10% Effort
 - Principal Investigator Individual R01 Project:
Obesity, Nitric Oxide, Oxidative Stress and Salt Sensitivity
15% Effort
2. Title: Community Network Program for Older Underserved African American Adults
Funding: NIH (NCI)
Purpose: To propose an active and comprehensive community-based program to reduce disparities of breast, prostate, colorectal, and lung cancer in older African American Adults in metropolitan Detroit.
Period: 04/01/05 through 03/31/10
Role: Co-Investigator
FTE: 10%
3. Title: Research Enhancement Grant
Funding: Wayne State University Office of the President & Provost
Purpose: To develop research infrastructure to enhance the conduct of multi-disciplinary, disparities related research.
Period: 11/2004-10/2007
Role: Principal Investigator
FTE: 0%
4. Title: Comprehensive Treatment and Support Intervention [CTSI-D] for Diabetes
Funding: International Society of Hypertension in Blacks/Association of Teachers in Preventive Medicine/Center for Disease Control
Purpose: Intervention to provide a comprehensive, evidence-based decision support to internal medicine house-officers and attendings using the MedTrace electronic medical clinical decision support system at two internal medicine resident clinics at major academic centers.
Period: 1/2002 through 09/2006
Role: Principal Investigator
FTE: 0%
5. Title: Nurse-Managed Blood Pressure Telemonitoring with African Americans
Funding: National Institute of Health
Purpose: To compare usual care only with home telemonitoring/telecounseling Plus usual care to determine which has the greatest effect on change in blood pressure from baseline; and to examine why the intervention works to control blood pressure by examining selected mediators, ie, dietary habits, physical

activity level, weight loss, reduced alcohol intake habits, physical activity level, weight loss, reduced alcohol intake, compliance with an antihypertensive medication regimen, and contact with primary care provider.

Period: 09/2000 through 09/2005
Role: Co-Investigator
FTE: 6%

6. Title: Secondary Prevention of Small Subcortical Strokes (SPS3)
Funding: University of Texas Health Science Center NIH-NINDS
Purpose: To define efficacious therapies for cerebral small artery disease and its two most common clinical manifestations: small subcortical strokes (S3) (a.k.a. lacunar strokes) and cognitive decline (vascular dementia)
Period: 03/2003-02/2004
Role: Co-Principal Investigator
FTE: 10%

7. Title: Multi-center, Double-blind, Randomized Placebo-controlled Parallel Group
Funding: _____
Purpose: 6-week study to evaluate the efficacy and safety of _____

Period: 05/20/2002 through 02/01/ 2003
Role: Principal Investigator
FTE: _____

8. Title: A 6-week Randomized, Open-label, Comparative Study to Evaluate the Efficacy and Safety of _____




Funding: _____
Purpose: _____


Period: 01/02/2002 through 05/15/2003
Role: Principal Investigator
FTE: _____

9. Title: A Randomized, Multicenter, Double-Blind, Parallel group Study to Determine the Safety and Efficacy _____

Funding: _____
Purpose: _____



Period: 12/2/2002 through 10/30/2003
Role: Principal Investigator
FTE: _____

10. Title: 
Funding: 
Purpose: 
Period: 5/2002-12/2002
Role: Principal Investigator
FTE:

11. Title: _____
Funding: _____
Purpose: 
Period: 6/4/2002-12/31/2007
Role: Principal Investigator
FTE:

12. Title: _____
Funding: _____
Purpose: (Investigator Initiated)
To determine impact of comprehensive electronic medical record populated with automated reminders and clinical decision support treatment algorithms on control of hypertension, diabetes, cholesterol in high-risk patients.
Period: 1/2001 through 8/31/2003
Role: Principal Investigator
FTE:

13. Title: _____
Funding: _____
Purpose: (Investigator Initiated)
Investigate or initiated proposal to determine the prevalence of erectile dysfunction and attitudes towards male sexual health in a national. Probability sample of 3000 men equally split between Whites, African Americans and Hispanics
Period: 5/1/2000 through-12/3/2001
Role: Principal Investigator, Advisory Panel Chairperson
FTE:

14. Title: A 12-Week, Multicenter, Double Blind, Parallel, 

Funding: _____

Purpose:

Period: 1998-ongoing
Role: National Principal Investigator of this Multicenter Clinical Trial

15. Title: Sodium and Angiotensin Peptide Protocol [SAAP] A Pilot Study
Funding: Internal Funding
Purpose: Evaluating the impact of dietary sodium consumption on both ambulatory and cuff blood pressure, arterial compliance and to correlate sodium consumption with markers of target-organ-damage in African American women with normal to high blood pressure.
Period: 1998
Role: Principal Investigator

16. Title: Hemodynamic Determinants of the Blood Pressure Response to Accumulated Physical Activity in African American Women
Funding: Harper Hospital Foundation
Purpose: To investigate the hemodynamic and hormonal effects of moderate intensity physical activity on sedentary African-American women with high-normal to stage 1 blood pressure evaluation.
Period: 1998-99
Role: Principal Investigator

17. Title:

Funding: _____
Purpose: Evaluate the efficacy, safety and tolerability of _____
Period: 1998
Role: Principal Investigator

18. Title: A Multicenter, Double-blind, randomized, parallel group, placebo-controlled _____
Funding: _____
Purpose: _____
Period: 1998
Role: National Principal Investigator of this Multicenter Clinical Trial

19. Title: A Multicenter, Single-Blind Trial Evaluating the Efficacy of _____
Funding: _____
Purpose: Evaluate efficacy of _____
Period: 1997
Role: Principal Investigator _____

20. Title:
Funding: _____
Purpose: _____
Period: 1998
Role: Principal Investigator
21. Title: _____
Funding: _____
Purpose: _____
Period: 1996-1998 (completed)
Role: Principal Investigator (Investigator Initiated)
22. Title: "RFA, Vascular Disease Academic Award
Funding: NHLBI HL-94-015/k07
Purpose: To promote the discipline of vascular medicine through teaching, clinical, and research activities.
Period: 1995-00
Role: Co-Principal Investigator/Medical Director
23. Title : _____
Funding: _____
Purpose: To compare the safety and effectiveness of _____
Period: 1995-95
Role: Co-Principal Investigator
24. Title: "Study of Coronary Heart Disease Risk Factors in Young Adults (CARDIA)"
Funding: National Heart Lung and Blood Institute NHLBI/NIH NO1 HV487048
Purpose: To monitor the evolution of cardiovascular risk factors and their determinants in a biracial cohort of young adults.
Period: 1993-94
Role: Principal Investigator
25. Title: "Women's Health Trial"
Funding: NIH - N01 WH3 2101
Purpose: A randomized, controlled, multicenter trial designed to evaluate the feasibility of recruiting women of different socio-economic status and minority groups and to determine whether these women can achieve and maintain low-fat eating habits.
Period: 1993-95
Role: Co-Principal Investigator (Dr. Grimm, Principal Investigator)
26. Title: "Multicenter Efficacy and Tolerability Study Comparing _____

-
- Funding: _____
Purpose: To examine the efficacy and tolerability of therapy with _____
-
- Period: 1993-95
Role: Principal Investigator
27. Title: "Healthy Eating and Lifestyle Program (HELP)"
Funding: American Heart Association and Medtronic Foundation;
Purpose: Attempt to decrease the prevalence of cardiovascular risk factors in two predominately African-American church congregation through peer counseling.
Period: 1993-94
Role: Principal Investigator
28. Title: "Sodium Sensitivity in Blacks" (SNaP)
Funding: NIH/NHLBI R01 - HL - 46630 - 01A1
Purpose: To identify factors which predict a pressor effect with sodium chloride administration in African Americans.
Period: 1992-94
Role: Co-Principal Investigator (Dr. Grimm, Principal Investigator)
29. Title: "Cranio-mandibular Disorders: Long-Term Outcome Study"
Funding: NIH
Purpose: To compare several different approaches to the management of TMJ disorders.
Period: 1992-97
Role: Co-Principal Investigator, Epidemiologist
30. Title: "Arterial Disease Multiple Intervention Trial (The ADMIT Study)"
Funding: NIH/NHLBI N01 HC25111
Purpose: To evaluate treatment and prevention strategies for atherosclerosis, cardiovascular disease clinical centers
Period: 1992-95
Role: Assistant Project Director (Dr. Hunninghake, Principal Investigator)
31. Title: _____
Funding: _____
Purpose: _____
-
- Period: 1991
Role: Principal Investigator (Investigator initiated)
32. Title: "Ambulatory Blood Pressure Study in USA Blacks and Liberian Immigrants"
Funding: BRSG, University of Minnesota
Purpose: To make preliminary observations regarding ambulatory blood pressure patterns in United States Blacks and Liberian Immigrants to obtain preliminary estimates of repeatability ambulatory blood pressure measurements in these unique populations.
Period: 1991-92

- Role: Principal Investigator
33. Title: "Feasibility of Reduction of Dietary Sodium in Black Participants"
Funding: BRSG
Purpose: To establish the methodology and demonstrate feasibility of this sodium reduction for an NIH proposal on the evaluation of the effect of dietary sodium intervention on blood pressure in Blacks and Whites.
Period: 1990-91
Role: Co-Principal Investigator
34. Title: "Lipid and Thiazide Study (LATS)"
Funding: Reuben Miller Cardiovascular Fund
Purpose: To support my ongoing research on the effects of thiazide diuretics on cholesterol distribution across LDL cholesterol subclasses.
Period: 1989-90
Role: Principal Investigator
35. Title: _____
Funding: _____
Purpose: _____

Period: 1988-92
Role: Co-Principal Investigator (_____, Principal Investigator)
36. Title: "The Effect of Thiazide Diuretics on LDL Cholesterol Subclasses"
Funding: University of Minnesota School of Public Health Biomedical Research Grant; #BRSG 0696-5725-95
Purpose: To assess the influence of thiazide diuretics on the distribution of cholesterol across LDL cholesterol subclasses.
Period: 1989-91
Role: Principal Investigator
37. Title: "Northeast Oklahoma City Cholesterol and Cardiovascular Risk Factor Screening and Education Program"
Funding: University of Oklahoma Health Sciences Center Biomedical Research Support Grant
Purpose: To conduct a church-based cholesterol education program.
Period: 1987-88
Role: Co-Principal Investigator (_____, Principal Investigator)
38. Title: _____

Funding: _____
Purpose: Obtain _____ safety data
Period: 1987-1988
Role: Principal Investigator
39. Title: "Treatment of Mild Hypertension Study (TOMHS)"
Funding: NHLBI/NIH R01 HL34767

Purpose: To determine optimal treatment of adults with mild diastolic hypertension (90-99 mmHg).
Period: 1985-1991
Role: Principal Investigator

BIBLIOGRAPHY

Publications in Refereed Journals

1. Grimm RH Jr, **Flack JM**, Byington R, Bond MG, Brugger S. For the MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extra cranial carotid atherosclerosis: The multicenter isradipine diuretic atherosclerosis Study. *Drugs (Suppl.2)*: 38-43,1990.
2. Wisst WH, **Flack JM**. A Church based cholesterol education program. *Public Health Rep.* 105(4):381-388, 1990.
3. McVeigh GE, Burns DE, Finkelstein SM, McDonald KM, Mock JE, Feske W, Carlyle PF, **Flack JM**, Grimm RH Jr, Cohn JN. Reduced vascular compliance as a marker for essential hypertension. *Am J Hypertension* 4, 3(3): 245-251, 1991.
4. Elmer PJ, Grimm RH Jr, **Flack JM**, Laing B. Dietary sodium reduction for hypertension prevention and treatment in clinical and community settings. *Hypertension* 17, 1(Suppl.1)(1): 1182-189, 1991.
5. Mascioli S, Launer C, Svendsen KH, **Flack JM**, Elmer P, Grimm RH Jr. Sodium chloride raises blood pressure in normotensives: The study of sodium and blood pressure (SNaP). *Hypertension* 17, 1(Suppl.1)(1): 121-26, 1991.
6. **Flack JM**, Ensrud KE, Launer CH, Mascioli SM, Svendsen KH, Elmer PJ, Grimm RH Jr. Racial and ethnic modifiers of the salt blood pressure response. *Hypertension* 17, 1(1): 115-121, 1991.
7. **Flack JM**, Sowers JR. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. *Am J Med* 91(Suppl.1A)(7): 11S-21S, 1991.
8. The Treatment of Mild Hypertension. A randomized, placebo controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. *Arch Int Med* 151(7): 1413-1423, 1991.
9. Bond MG, Mercuri M, Nichols FT, Khoury SA, **Flack JM**, Carr AA. Antiatherosclerosis clinical trials using calcium antagonists. *J Vasc Med Biol* 3, 5(10): 392-401, 1991.
10. Oparil S, Berenson GB, Esler M, Falkner B, **Flack JM**, Grim C, Jesse MJ, Roccella EJ, Saunders E, Weinberger M. Epidemiology and classification of hypertension. (workshop) *Hypertension* 18, 9(Suppl.3)(9): 92-94, 1991.
11. **Flack JM**, Wiist WH. Cardiovascular risk factor prevalence in African American adult screenees of a church-based cholesterol education program: The Northeast Oklahoma City Cholesterol Education Program (NEOCEP). *J Ethnicity Dis* 1: 78-90, 1991.
12. Belcher JD, Egan JO, Bridgman G, Baker R, **Flack JM**. A micro enzymatic method to measure cholesterol and triglyceride in lipoprotein subfractions separated by density

- gradients ultracentrifugation from 200 microliters of plasma or serum. *J Lipid Res* 32: 359-370, 1991.
13. Folsom AR, Burke GL, Byers CL, Hutchinson RG, Heiss G, **Flack JM**, Jacobs DR Jr, Caan B. Implications of obesity for cardiovascular disease in blacks: the CARDIA and ARIC Studies. *Am J Clin Nutr* 53: 1604S-1611S, 1991. (Published erratum appears in the *Am J Clin Nutr* 54,3: 590, 1991).
 14. **Flack JM**, Wiist WH. Epidemiology of hypertension and hypertensive target organ damage in the United States. *J Assoc Acad Minority Phys* 2, 4: 143-150, 1991.
 15. **Flack JM**, Esunge P, Grimm RH Jr. Isolated systolic hypertension: An approach to treatment. *Illus Med* 7, 1: 2-16, 1992.
 16. Melnick SL, Sprafka JM, Bostick RM, **Flack JM**, Burke GL. Antibiotic use in urban Whites and Blacks: The Minnesota Heart Survey. *Ann Pharmacother* 26(10): 1292-1295, 1992.
 17. **Flack JM**, Woolley A, Esunge P, Grimm RH Jr. A rational approach to hypertension treatment in the older patient. *Geriatrics* 47, 11(11): 24-38, 1992.
 18. Wiist WH, **Flack JM**. A Test of the John Henryism Hypothesis: Cholesterol and blood pressure. *J Behav Med* 15, 1: 15-29, 1992.
 19. Borhani NO, Miller ST, Brugger SB, Schnaper HW, Craven TE, Bond MG, Khoury SA, **Flack JM**. MIDAS: Hypertension and atherosclerosis. A trial of the effects of antihypertensive drug treatment on atherosclerosis. *J Cardiovasc Pharmacol* 19 (Suppl.3): S16-S20, 1992.
 20. Liebson PR, Grandits GA, Prineas RJ, Dianzumba S, **Flack JM**, Cutler JA, Grimm RH Jr, Stamler J. Echocardiographic correlates of left ventricular structure among 844 mild hypertensive men and women in the treatment of mild hypertension study (TOMHS). *Circulation* 87, 2(2): 476-486, 1993.
 21. **Flack JM**, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease: Lessons from multiple risk factor intervention trial and the treatment of mild hypertension Study. *Am J Kidney Dis* 21, 4(Suppl.1)(4): 31-40, 1993.
 22. Wilt TJ, Sprinkle JW, **Flack JM**, Heuer C, Borhani NO, Merchant A, Schnaper HW, Applegate W, Grimm RH Jr. Prevalence and correlates of lower extremity arterial disease in hypertensive patients with carotid atherosclerosis: Baseline results from the multicenter isradipine/diuretic atherosclerosis study (MIDAS). *J Vasc Med Biol* 4, 2-3(4): 95-101, 1993.
 23. Bradley K, **Flack JM**, Belcher JD, Elmer PJ, Miller P, Grimm RH Jr. Chlorthalidone attenuates the reduction in total cholesterol and small, dense LDL cholesterol subclass associated with weight loss. *Am J Hypertension* 6, 7(7): 636-39, 1993.
 24. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, **Flack JM**, Schoenberger JA, McDonald R, Lewis CE, Liebson PR. Treatment of mild hypertension study (TOMHS) final results. *J Am Med Assoc* 270, 6(8): 713-724, 1993.

25. Perloff D, Grim C, **Flack JM**, Frohlich ED, Hill M, McDonald M, Morgenstern BZ. Human blood pressure determination by sphygmomanometry. writing group. *Circulation* 88, 5(11): 2460-2470, 1993.
26. Folsom AR, Qamheih HT, **Flack JM**, Hilner JE, Liu K, Howard BV, Tracy RP. Plasma fibrinogen: levels and correlates of young adults. The coronary artery risk development in young adults (CARDIA) study. *Am J Epidemiol* 138, 12(12): 1023-1036, 1993.
27. Kaye SA, Folsom AR, Jacobs DR Jr, Hughes GH, **Flack JM**. Psychosocial correlates of body fat distribution in Black and White young adults. *Int J Obesity* 17: 271-277, 1993.
28. **Flack JM**, McVeigh GE, Grimm RH Jr. Hypertension therapy in the elderly. *Curr Opinion Nephrol* 2: 386-394, 1993.
29. Mercuri M, Bond MG, Nichols FT, Carr AA, **Flack JM**, Byington R, Raines J. For the MIDAS Group. Baseline reproducibility of B-mode ultrasound imaging measurements of carotid intima-media thickness: The multicenter isradipine diuretic atherosclerosis study (MIDAS). *J Cardiovasc Diabetes Proc II* 4(2): 241-256, 1993.
30. Howard BV, Le NA, Belcher JD, **Flack JM**, Jacobs DR Jr, Lewis CE, Marcovina SM, Perkins LL. Concentrations of Lp(a) in Black and White young adults: Relation to risk factors for cardiovascular disease. *Ann Epidemiol* 4, 5(9): 341-350 1994.
31. **Flack JM**. High blood pressure in older persons: A high-risk special population. *Can J Public Health* 85(Suppl.2)(9): S9-11, 1994
32. **Flack JM**, Ryder KW, Strickland D, Whang R. Metabolic correlates of theophylline therapy - A concentration-related phenomena. *Ann Pharmacother* 28(2): 175-179, 1994.
33. Kvasnicka J, **Flack JM**, Grimm RH Jr. Treatment of hypertension in the presence of coexisting medical conditions. *Drugs & Aging* 4, 4: 304-312, 1994.
34. Abraham PA, Mascioli SM, Launer CH, **Flack JM**, Liebson PR, Svendsen KH, Grandits GA, Opsahl JA, Schoenberger JA, Grimm RH Jr. Urinary albumin and N-acetyl-beta-D-glucosaminidase excretions in mild hypertension. *Am J Hypertension* 7, 11(11): 965-974, 1994.
35. Rinehart AL, Herzog CA, Collins AJ, **Flack JM**, Ma JZ, Opsahl JA. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. *Am J Kidney Dis* 25, 2(2): 281-290, 1995.
36. Wright JT Jr., **Flack JM**. Diuretics - what role for reduction of cardiovascular disease risk in African-Americans? *Cholesterol and coronary disease reducing the risk* 5, 1: 15-18, 1994.
37. Gidding SS, Xie X, Liu K, Manolio T, **Flack JM**, Gardin JM. Cardiac function in smokers and nonsmokers. The CARDIA Study. *J Am Coll Cardiol* 26, 1(7): 211-216, 1995.
38. Hoegerman GS, Lewis CE, **Flack JM**, Raczynski JM, Caveny J, Gardin JM. Lack of association of recreational cocaine and alcohol use with left ventricular mass in young adults. The coronary artery risk development in young adults (CARDIA) Study. *J Am Coll Cardiol* 25, 4(3): 895-900, 1995.

39. **Flack, JM**, Mensah, McVeigh GE, Weir MR, Reed J. Diagnosis, evaluation and management of hypertension in an ambulatory clinic setting. *J Clin Outcomes Mgt* 2, 5(9): 39, 44-58, 62-66, 1995.
40. **Flack JM**, Neaton JD, Grimm RH Jr, Cutler JA, Shih J, Ensrud K, MacMahon S. Blood pressure and mortality among men with prior myocardial infarction. *Circulation* 92, 9(9): 2437-2445, 1995.
41. **Flack JM**. Systolic hypertension: Worth treating? *The Kidney* 1(1), 1995.
42. Zhang S, Folsom AR, **Flack JM**, Liu K. Body fat distribution before pregnancy and gestational diabetes: Findings from coronary artery risk development in young adults (CARDIA) Study. *Brit Med J* 311(10): 1139-1140, 1995.
43. **Flack JM**, Amaro H, Jenkins W, Kunitz S, Levy J, Mixon M, Yu E. Epidemiology of minority health. *Health Psychol* 14, 7: 592-600, 1995.
44. **Flack JM**. Linking the medical and public health approaches for the prevention, management, and control of hypertension in the African American population: What steps can we take today? *J Nat Med Assoc* 87: 657-658, 1995.
45. McVeigh GE, **Flack JM**, Grimm RH Jr. Goals of antihypertensive therapy. *Drugs* 49, 2: 161-175, 1995.
46. Lewis CE, Grandits GA, **Flack JM**, McDonald R, Elmer PJ. Efficacy and tolerance of antihypertensive treatment in men and women with stage I diastolic hypertension. Results of the treatment of mild hypertension study. *Arch Int Med* 156 (2): 377-385, 1996.
47. Liu K, Ruth KJ, **Flack JM**, Jones-Webb R, Burke GL, Savage PJ, Hulley SB. Blood pressure in young Black and Whites: Relevance of obesity and lifestyle factors in determining differences -- The CARDIA Study. *Circulation* 93, 1(1): 60-66, 1996.
48. Maron BJ, Gardin JM, **Flack JM**, Gidding SS, Bild DE. HCM in the general population. *Circulation* 94, 3(8): 588-589, 1996.
49. Jones-Webb R, Jacobs DR Jr, **Flack JM**, Liu K. Relationships between depressive symptoms, anxiety, alcohol consumption, and blood pressure: Results from the CARDIA Study. *J Alcoholism: Clini Expt Res. Alcohol Clin Exp Res* 20, 3(5): 420-427, 1996.
50. Grimm RH Jr, **Flack JM**, Schoenberger JA, Gonzalez N, Liebson PR. Alpha blockade and thiazide treatment of hypertension: A double-blind randomized trial comparing doxazosin and hydrochlorothiazide. *Am J Hypertension*. 9, 5(5): 445-454, 1996.
51. Weir MR, Bakris GL, Toto RD, **Flack JM**, Williams B, Neutel J. Hypertension. *Curr Nephrol* 19: 203-241, 1996.
52. Weir MR, **Flack JM**, Applegate WB. Tolerability, safety and quality of life and hypertensive therapy: The case for low dose diuretics. *Am J Med* 101 (Suppl.3A)(9): 83S-92S, 1996.

53. National High Blood Pressure Education Program. 1995 update of the working group reports on chronic renal failure and renovascular hypertension. *Arch Int Med* 156 (9): 1928-1947, 1996.
54. Ferrario CM, **Flack JM**. Pathological consequences of increased angiotensin II activity. *Cardiovas Drug Ther* 10: 511-518, 1996.
55. Markovitz JH, Raczynski JM, Lewis CE, **Flack JM**, Chesney M, Chettur V, Hardin JM, Johnson E. Lack of independent relationships between left ventricular mass and cardiovascular reactivity to physical and psychological stress in the coronary artery risk development in young adults (CARDIA) study. *Am J Hypertension* 9, 9(9): 915-923, 1996.
56. Folsom AR, Jacobs DR Jr, Wagenknecht LE, Winkhart SP, Yunis C, Hilner JE, Savage PJ, Smith DE, **Flack JM**. Increase in fasting insulin and glucose over seven years with increasing weight and inactivity of young adults. The CARDIA Study. *Am J Epidemiol* 144, 3: 235-246, 1996.
57. **Flack JM**. Benefits of adherence to antihypertensive drug therapy. *Europ Heart J* 17A (Suppl.A): 16-20, 1996.
58. **Flack JM**, Cushman W. Evidence of the efficacy of low-dose diuretic monotherapy. *Am J Med* 101(Suppl 3A): 53S-60S, 1996.
59. Gidding SS, Liu K, Bild DE, **Flack JM**, Gardin JM, Ruth KJ, Oberman A. Prevalence and identification of abnormal lipoprotein levels in a biracial population aged 23 to 35 years. The coronary artery risk development in young adults study (CARDIA). *Am J Cardiol* 78: 304-308, 1996.
60. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). *Arch Intern Med* 157:2413-2446, 1997.
61. Gimm RH Jr, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, **Flack JM**, Yunis C, Svendsen KH, Liebson PR, Elmer PJ, Stamler J, for the TOMHS Research Group. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of mild hypertension study (TOMHS). *Hypertension* 29, 1(1): 8-14, 1997.
62. Weir MR, Hall PS, Behrens MT, **Flack JM**. Salt and blood pressure responses to calcium antagonism in hypertensive patients. *Hypertension* 30, 3(9): 422-427, 1997.
63. Hall WD, Ferrario CM, Moore MA, Hall JE, **Flack JM**, Cooper W, Simmons JD, Egan BM, Lackland DT, Perry M, Jr., Roccella EJ. Hypertension-related morbidity and mortality in Southeastern United States. *Am J Med Sci* 313, 4(4): 195-209, 1997.
64. **Flack JM**, Yunis C. Therapeutic implications of the epidemiology and timing of myocardial infarction and other cardiovascular diseases. *J Human Hypertension* 11: 23-28, 1997.
65. **Flack JM**. Epidemiology of cardiovascular disease & target organ injury in African Americans. *Med Roundtable* (11): 3-4, 1997.

66. Deitch JS, Hansen KJ, Craven TE, **Flack JM**, Appel RG, Dean RH. Renal artery repair in African Americans. *J Vasc Surg* 26, 3(9): 465-72, discussion 473, 1997.
67. Ganguli MC, Grimm RH Jr, Svendsen KH, **Flack JM**, Grandits GA, Elmer PJ. Higher education and income are related to better Na:K ratio in blacks: Baseline results of the treatment of mild hypertension (TOMHS) data. *Am J Hypertension* 10, 9(9): 979-984, 1997.
68. **Flack JM**, The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JVNC VI). *Arch Intern Med* 157(21): 2413-2446, 1997.
69. Larochelle P, **Flack JM**, Marbury TC, Sareli P, Krieger EM, Reeves RA for the Irbesartan Multicenter Investigators, Antihypertensive effects and tolerability of irbesartan versus enalapril: A randomized trial in-patients with severe hypertension. *Am J Cardiol* 80(2): 1612-1615, 1997.
70. Weir MR, Bakris GL, Toto RD, **Flack JM**, Bravo EI. Hypertension. *Curr Nephrol* 20: 209-241, 1997.
71. **Flack JM**, Hamaty M, Staffileno B. Renin-angiotensin-aldosterone-kinin system influences on diabetic vascular disease and cardiomyopathy. *Miner Electrolyte Metab* 24: 412-422, 1998.
72. **Flack JM**, Staffileno BA. Therapeutic strategies for hypertension treatment in patients with selected cardiovascular disease. *Drugs of Today* 34, 9: 813-822, 1998.
73. Hall WD, Reed JW, **Flack JM**, Yunis C, Preisser J. Comparison of efficacy dihydropyridine calcium channel blockers in African American patients with hypertension. *Arch Int Med* 158(18): 2029-2034, 1998.
74. Ferrario CM, Martel N, Yunis C, **Flack JM**, Chappell MC, Brosnihan KB, Dean RH, Fernandez A, Novikov SV, Pinillas C, Luque M. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. *Am J Hypertension II* 2(2): 137-146, 1998.
75. Ganguli MC, Grimm RH, Svendsen KH, **Flack JM**, Grandits GA, Elmer PJ, Urinary sodium and potassium profile of blacks and whites in relation to education in two different geographic urban areas. TOMHS Research Group. Treatment of Mild Hypertension study. *AM J Hypertens* 12(1 Pt 1):69-72 Jan, 1999.
76. **Flack JM**, Hamaty M. Difficult-to-treat hypertensive population: focus on AA and people with type 2 diabetes. *J Hypertension* 17 (Suppl.1): S19-S24, 1999.
77. **Flack JM**, Optimal blood pressure on antihypertensive medication. *Current Hypertension Reports* I(5):381-386. 1999.
78. Raskin P, Guthrie R, **Flack JM**, Reeves R, Saini R. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. *J Hum Hypertens* 13 (10): 683-7, 1999.

79. **Flack JM**, Kvasnicka J, Gardin J, Gidding S, Manolio T, Jacobs DR Jr. Anthropometric and physiologic correlates in mitral valve prolapse in a biethnic cohort of young adults: The CARDIA Study. *Am Heart J* 138 (3 Pt 1): 486-92, 1999.
80. **Flack JM**, Gardin JM, Yunis C, Liu K. Static and pulsatile blood pressure correlates of left ventricular structure in a biethnic cohort of young adults: The CARDIA study. *Am Heart J* 138 (3 Pt 1): 856-64, 1999.
81. **Flack JM**, Mann N, Renovascular Hypertension. *Clinical cases in hypertension special treatment strategies*. Vol 2: 86-93, 2000.
82. **Flack JM**, Mensah GA, Ferrario CM. Using angiotensin converting enzyme inhibitors in African American hypertensives: A new approach to treating hypertension and preventing target-organ damage. *Curr Med Res Opin* 16(2):66-79, 2000.
83. **Flack JM**, Yunis C, Preisser J, et al. The rapidity of drug dose escalation influences blood pressure response adverse side effects burden in patients with hypertension: The quinapril titration interval management evaluation (ATIME) study. *Arch Intern Med* 160(12):1842-7, 2000.
84. Peters, RM, **Flack, JM**. Salt-sensitivity and hypertension in African Americans: implications for cardiovascular nurses: *Prog Cardiovascular Nursing* 15(4):138-144 April, 2000.
85. **Flack JM**, Saunders E, Gradman A, et al. Antihypertensive efficacy and safety of losartan alone and combination with hydrochlorothiazide in African Americans with mild-to-moderate hypertension. *Clinical Therapeutics* 23 (8) 1193-1208, 2001.
86. Clark LT, Ferdinand KC, **Flack JM**, Gavin Jr. III, Hall WD, Kumanyika SK, Reed JW, Saunders E, Valantine HA, Watson K, Wenger NK, Wright JT. Coronary heart disease in African-Americans: (African American Lipid Council) AALC, *Heart Disease* (3) 97-108, 2001.
87. **Flack JM**, Ramappa P, Jones S, Alrefai H. Hypertension in the geriatric patient. *Infertility and Reproductive Medicine Clinics of North American* 12(3) 535-547, July 2001.
88. **Flack, JM**. The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia hypertension, or both. *Int J Clin Pract* 56(7): 527-530, Sept 2002.
89. Crook ED, Washington DO, **Flack JM**. Screening and prevention of chronic kidney disease. *J of the Nat Med Ass*, Vol 94(8): 55S-62S, Aug 2002.
90. **Flack JM**, Peters R, Mehra V, Nasser S. Hypertension in special populations. *Cardio Clin* Vol 20(2): 303-319, May 2002.
91. **Flack JM**. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis. *Curr Hypertens Rep* 4(3):183-4 June, 2002.
92. **Flack JM**, Grimm RH. Jr, Staffileno BA, Elmer P, Yunis C, Hedquist L, Dudley, A. New salt-sensitivity metrics: variability-adjusted blood pressure change and the urinary sodium to creatinine ratio. *Eth and Dis*, Vol 12(1):10-19, 2002.
93. Kostis JB, Cobbe S, Johnston C, Ford I, Murphy M, Weber MA, Black HR, Plouin PF, Levy D, Mancina G, Laroche P, Kolloch RE, Alderman M, Ruilope LM, Dahlof B, **Flack JM**,

- Wolf R. Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (OPERA) trial. *Am J Hypertens* 15(2 Pt 1):193-8 Feb, 2002.
94. **Flack JM**, Casciano R, Casciano J, Doyle J, Arikian S., Tang S, Arocho P. Cardiovascular disease costs associated with uncontrolled hypertension. *Manag Care Interface*; Vol 15(11):28-36, Nov 2002.
95. Brown WW, Davis J, **Flack JM**, Gannon MR. NKF's KEEP leads to longitudinal study. *Nephrol News*; Vol 16(12) 84-86, Nov 2002.
96. Crook ED, **Flack JM**, Salem M, Salahudeen AK, Hall J. Primary renal disease as a cardiovascular risk factor. *Am J Med Sci* Vol 324(3):138-145, Sept 2002.
97. Hall DW, Clark LT, Wenger NK, Wright TW Jr, Kumanyika SK, Watson K, Horton EW, **Flack JM**, Ferdinand KC, Reed JW, Saunders E, O'Neal W Jr. What is the metabolic syndrome and why is it important? *Ethn Dis* 13 (4): 546, Fall 2003.
98. Hall DW, Clark LT, Wenger NK, Wright TW Jr, Kumanyika SK, Watson K, Horton EW, **Flack JM**, Ferdinand KC, Garin JR 3rd, Reed JW, Saunders E. Metabolic Syndrome in African Americans: A Review. *Ethn Dis* 13(4):414-28, Fall 2003
99. Ohmit SE, **Flack JM**, Peters RM, Brown WW, Grimm R. Longitudinal Study of the National Kidney Foundation's (NKF) Kidney Early Evaluation Program (KEEP). *J of the Amer Society of Nephrology*, *J Am Soc Nephrol*; 14(7 suppl 2): S117-21, July 2003.
100. Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, King K, Klag MJ, Molony DA, **Flack JM**. Early detection of kidney disease in community settings: The kidney early evaluation program (KEEP). *Am J Kidney Dis*; 42(1):22-35, July 2003.
101. **Flack JM**, Peters R, Shafi T, Alrefai H, Nasser SA, Crook E. Prevention of hypertension and its complications: Theoretical basis and guidelines for treatment. *J of the Amer Society of Nephrology*, *J Am Soc Nephrol*; 14(7 suppl 2):592-8, July 2003.
102. Crook ED, Thallapureddy A, Migdal S, **Flack JM**, Greene EL, Salahudeen A, Tucker JK, Taylor HA Jr. Lipid abnormalities and renal disease: Is dyslipidemia a predictor of progression of renal disease? *Am J Med Sci*; 325(6):340-8, June 2003.
103. Crook ED, Clark BL, Bradford ST, Golden K, Calvin R, Taylor HA Jr, **Flack JM**. From 1960s Evans County Georgia to present-day Jackson, Mississippi: an exploration of the evolution of cardiovascular disease in African Americans. *Am J Med Sci*; 325(6):307-14, June 2003.
104. **Flack JM**, Nasser SA. The Antihypertensive and lipid-Lowering treatment to prevent heart attack trial (ALLHAT). *Curr Hypertens Rep*;5(3):189-91, June 2003.
105. **Flack JM**, Ferdinand KC, Nasser SA. Epidemiology of hypertension and cardiovascular disease in African Americans. *J of Clin Hyper Supp* Vol V(1): 5-11, Feb 2003.
106. Peters RM, **Flack, JM**. Diagnosis and treatment of hypertension in children and adolescents. *Clinical Practice* Vol 15(2): 56-53, Feb 2003.

107. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, **Flack JM**, Jamerson KA, et al for the ISHIB Hypertension in African Americans Working Group. Management of high blood pressure in African Americans, *Arch Intern Med*; 163(5):525-41, March, 2003.
108. **Flack JM**, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. *J Am Coll Cardiol*; 41(7):1148-55 April, 2003.
109. King TE, Wesson DE, Dickinson TA, DuBose TD, **Flack JM**, Hellmann DB, et al. The Case for Diversity in Academic Internal Medicine. *AM J Med* 2004; 116(4):284-289.
110. Peters RM, **Flack, JM**. Hypertension disorders of pregnancy. *J of Obstetric Gynecological & Neonatal Nsg. JOGNN* Vol 33(2): 209-220, March/April, 2004.
111. Mokwe E., Ohmit SE, Nasser SA, Shafi T, Saunders E, Crook ED, Dudley A, **Flack JM**. Determinants of blood pressure response to quinapril in black and white hypertensive patients. *Hypertension* 43(6): 1202-7, June 2004.
112. **Flack, JM**. Calcium antagonist strategies for coronary artery disease. *Current Hypertension Reports* 6(3): 161-3, June 2004.
113. El-Akchar T, Ohmit S, McCullough P, Crook E, Brown W, Grimm R, Bakris G, Keane W, **Flack JM**. Higher prevalence of anemia with diabetes mellitus in men in moderate kidney insufficiency: The Kidney Early Evaluation Program. *Kidney International*. 67 (4): 1483-8. April 2005.
114. Weir MR, Ferdinand KC, Saunders E, **Flack JM**, Jamerson KA, Daley W, Zelenkofske S. Comparison of Valsartan/HCTZ and Amlodipine in African Americans. *Hypertension*, (manuscript submitted) 2005.
115. **Flack JM**, Sica D. Therapeutic Considerations in the African American Patient with Hypertension: Considerations with Calcium Channel Blocker Therapy. *Journal of Clinical Hypertension*. 7(4 Suppl 1): 9-14, April 2005.
116. **Flack JM**. The Camelot Trial. *Current Hypertension Reports*, 2005; 7(3):165-167.
117. Clark R, Benkert R A, **Flack JM**. Large Arterial Elasticity Varies as a Function of Gender and Racism-Related Vigilance in Black Youth, (manuscript submitted) 2005.
118. Benjamin EJ, Jessup M, **Flack JM**, et al for the 2003 Writing Group Outcomes: Impact from Observational Studies. "Discovering the Full Spectrum of Cardiovascular Disease Disparities: the Minority Health Summit 2003: Report of the Outcomes Writing Group. *Circulation*. 111 (10): e124-33, March 15, 2005.
119. Kaufman JS, **Flack JM**. Angiotensin-converting enzyme inhibitors in black patients. *Ann Intern Med*. 142 (7):589, Apr 5 2005.
120. Peters RM, Aroian KJ, **Flack JM**. African American Culture and Hypertension Prevention. (manuscript submitted) 2005.

121. **Flack JM**, Bakris GL, McGregor J, Purkayastha D, Gatlin M. Angiotensin-Converting Enzyme Inhibitor/Calcium Channel Blocker Therapy in African Americans with Type 2 Diabetes. (manuscript submitted) 2005.
122. Weir MR, Ferdinand KC, **Flack JM**, Jamerson KA, Daleys W, Zelenkofske S. A non-inferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. *Hypertension* 2005; 46(3): 508-513.
123. McFarlane SI, Castro J, Kaur J, Shin JJ, Kelling D Jr, Faraq A, Simon N, El-Atat F, Sacerdote A, Basta E, **Flack JM**, Bakris G, Sower JR. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. *J Clin Hypertens* 2005; 7(2):73-80.
124. Clark R, Benkert RA, **Flack JM** Violence exposure and optimism predict task-induced changes in blood pressure and pulse rate in a normotensive sample of inner-city black youth. *Psychosomatic Medicine* 2006 Jan-Feb;68(1):73-9.
125. Wesson DE, King TE Jr., Todd RF, Torres EA, Hellman DB, **Flack JM**, Dubose TD Jr., Schuster VL. Achieving diversity in Academic Internal Medicine; recommendations for leaders. *Am J Med.* 2006 Jan;119(1):76-81.

Peer-Reviewed Book Chapters

1. **Flack JM**, Grimm RH Jr. Diuretics, Kaplan NM, Brenner BM, Laragh JH, (eds). In Perspectives in hypertension Vol. III, New therapeutic strategies in hypertension. Raven Press Ltd. 1989, pp 17-32.
2. **Flack JM**, Yunis C. Ethnicity, SES, and hypertension. Izzo JL, Black HR (eds) In American Heart Association Hypertension primer. American Heart Association, Dallas, Tx 1993, pp153-155.
3. **Flack JM**, Staffileno BA. Hypertension in blacks. Richard Johnson, MD (ed) In Comprehensive clinical nephrology, Mosby International. London, UK, 1998.
4. **Flack JM**, Weir MW, and Calcium antagonists as antihypertensive in African-American patients. Murray Epstein, MD FACP, (ed). In Calcium antagonists in clinical medicine, 2nd Edition. Huskey and Belfur Inc., pp. 291-305. Philadelphia, PA 1998.
5. **Flack JM**, Staffileno BA. Hypertension in Blacks, in Oparil and Webber (eds.), In Hypertension: A companion to Brenner and Rector's the kidney, W.B. Saunders, (62): pp 558-563. Philadelphia, PA 2000
6. **Flack JM**. Therapy of hypertension in primer on kidney diseases. Arthur Greenberg, (ed). Alfred K. Cheung et al (assoc ed). In Primer on kidney diseases, 2nd Edition. Academic Press, pp. 486-497. San Diego, CA 2001
7. **Flack JM**, Mann NK, Ramappa P., Rangi JK, Hypertension and other risk factors for stroke, Braithwaite RL and Taylor SE (eds) in Health/issues in the black community, 2nd edition, Jossey-Bass publishers, pp 189-208. San Francisco, CA 2001.

John M. Flack, M.D., M.P.H.

8. **Flack JM.** Drugs for Hypertension. Reed JW, Hudson HM (eds), in High blood pressure: the black man and woman's guide to living with hypertension, Hilton Publishing, Chapter 5 pp 63-82. Roscoe, IL 2002.
9. **Flack JM, Nasser SA.** Ethnicity and Socioeconomic Status in Hypertension, Izzo JL and Black HR (eds). In American Heart Association Hypertension primer. 3rd Edition, Chapter B88, pp 261-264. 2003.
10. **Flack JM, Patel N, Mehra Vishal, Nasser SA.** Hypertension treatment, Chaturvedi S, Levine SR (eds), in Transient ischemic attacks, Blackwell Futura Publishing, Chapter 14 pp 309-323. Malden, Massachusetts 2004

Non-Peer Reviewed Book Chapters

1. **Flack JM.** Atherosclerosis. Kaufman CE, and Clark B, Eds. Pathophysiology syllabus 1987-1988 University of Oklahoma, Oklahoma City 147-164, 1987.

Non-Peer Reviewed Articles

1. **Flack JM.** Assessing functional outcomes in hypertension. Group practice J 41(3):82-85, 1992.
2. Grimm RH Jr, **Flack JM.** The management of hypertension: Potential trade-offs on coronary risk. Am J Med 87(2A):625-655, 1989.
3. **Flack JM, Grimm RH Jr.** Treating hypertension and lipids: A rational approach. Med Mgt Dynamics 6:3-8, 1988.
4. **Flack JM.** Living with hypertension. Introduction to dealing with elevated blood pressure. NC Med J 58(3):193-196, 1997.

Editorials

1. **Flack JM.** Sisson L. Obesity is a major crisis for African-Americans. Obesity and health 5(1):5-6, 1991.
2. **Flack JM.** Lifestyle modification and blood pressure: Lessons from TOMHS. Obesity and Health 6(6):106-107, 1992.
3. **Flack JM.** Calcium antagonists: friend, foe, or do we know? Consortium of southeastern hypertension centers newsletter, 1996.
4. **Flack JM.** Bledsoe K. Combination antihypertensive drug treatment: A therapeutic option long overdue. American family physician 61(10):2974-2977, 2000.
5. **Flack JM,** Minimizing the progression of kidney disease: AM J of Kidney Disease 36 (3) Suppl 1:S1-S3, 2000.
6. Ofili E, **Flack JM,** Gibbons G. Race and responsiveness to drugs for heart failure. N Engl J Med 6;345(10):767; discussion 767-8, Sept 2001.

7. **Flack JM**, Crook ED, Klag M. Racial and ethnic disparities in kidney disease. *Adv Ren Ther*; 11(1) editorial 1-2, Jan 2004.

Manuscripts in Preparation

- 1.
- 2.



Published Abstracts

1. Gardin JM, Wagenknecht LE, Anton-Culver H, **Flack JM**, Gidding S, Wong ND, Manolio TA. Relationship of Race, sex, systolic blood pressure levels, and body mass to left ventricular mass in healthy young adults. The CARDIA Study. *Circulation* 84(4):133, 1991.
2. **Flack JM**, Gardin JM, Gidding S, Manolio TA, Sedlacek C, Nelson E, Jacobs DR. Mitral valve prolapse in a biracial cohort of young adults. The CARDIA Study. *Circulation* 84(4):130, 1991.
3. **Flack JM**, Liu K, Savage P. Baseline insulin predicts 2 year blood pressure changes in young adults. The CARDIA Study. *Circulation* 83(2):724, 1991.
4. Gidding S, Liu K, Gardin J, **Flack JM**, Hulley S. Ability of NCEP guidelines to identify young adults with high LDL cholesterol: The CARDIA Study. *Circulation* 83(2):731, 1991.
5. Gidding S, Liu K, Bild D, Wagenknecht L, **Flack JM**, Hulley S. Use of life style factors to identify young adults with low HDL cholesterol: The CARDIA Study. *Circulation* 83(2):732, 1991.
6. **Flack JM**, Adams-Campbell L, Gardin J, Yunis C, Lewis B, Levin R. Psychosocial correlates of left ventricular mass (LVM) in young adults: The CARDIA Study. *Am J Hypertension* 6(5 Part 2):22A, 1993.
7. Mercuri M, Bond M, Nichols F, Carr A, **Flack JM**, Byington R, Raines J. For the MIDAS Group. *J Cardiovasc Diag Proc* 11(4):241-256,1993.
8. **Flack JM**, Yunis C, Preisser J, Staffileno BA, Menssah G, Saunders E. The accupril titration interval management evaluation (ATIME) trial. *Am J Hypertension* 11(4); Part 2; 103 A, 1998.
9. **Flack JM**, Grimm RH, Staffileno BA, Yunis C, Elmer P. A Novel Z-Score method for determining salt-sensitivity: The sodium and blood pressure study (SNAP). *Hypertension* 32(3): 606, 1998.
10. Staffileno BA, Braun LT, **Flack JM**. The accumulative effects of physical activity in hypertensive post-menopause women. *Med Sci Sports Exerc* 30(5): Suppl; 582, 1998.
11. Staffileno BA, **Flack JM**, Brauen LT. Hemodynamic response from the accumulation of short bouts of moderate-intensity physical activity in hypertensive, postmenopausal women. *Am J Hypertension* 11(4): Part 2: 209A, 1998.

12. **Flack JM**, Grimm RH, Staffileno BA, Elmer P, Yunis C, Peters R. The influence of body mass index on salt-sensitivity in African American women: the sodium and blood pressure study [SNAP]. *Ethnicity & Disease* 8 (2), 1998.
13. Holmes CB, Staffileno BA, Hamaty M, Dudley A, Yunis C, Grimm RH, **Flack JM**. The interactive effect of body size and renin-angiotensin axis on blood pressure response to oral salt loading in normotensive African Americans. *Am J Hypertension* 12(4): Part 2: 17A – 18A, 1999.
14. Grimm RH, Bracha Y, **Flack JM**, Grandits G, Prineas R. Reasons for going off study medication in the Treatment of Mild Hypertension Study. (American Society of Hypertension [ASH], Annual Scientific Meeting, 2000
15. Duncan K, Ramappa P, Thornburg R, Singh K, Okoye C, Mann N, Hedquist L, Dudley A, **Flack JM**. The influence of urinary albumin excretion and estimated glomerular filtration rate on blood pressure response in drug-treated hypertensive patients in an academic hypertension clinic. *Am J Hypertension* 14(4): Part 2: P-493, 2001.
16. Thornburg R, Ramappa P, Singh K, Okoye, Dudley A, Hedquist L, Mann N, **Flack JM**. Factors correlated to blood pressure response in hypertensive patients with Type 2 diabetes mellitus. *Am J Hypertension* 14(4): Part 2: P-578, 2001.
17. **Flack JM**, Garza D, Shi, Amlodipine Study Group. A multicenter single-blind trial evaluating the efficacy of amlodipine in patients with severe hypertension (JNC Stage 3). *Am J Hypertension* (14)4: Part 2: P-242, 2001.
18. Kostis JB, Cobbe S, Johnston C, Ford I, Murphy M, Webber MA, Black HR, Plouin PF, Levy D, Mancia G, Laroche P, Kolloch RE, Alderman M, Ruilope LM, Dahlof B, **Flack JM**, Wolf R. OPERA Study Group. Omapatrilat in persons with enhanced risk of atherosclerotic events. *Am J Hypertension* (14)2: Part 1:P193-8, 2002.
19. **Flack JM**, Bakris G. LEAAD (Lotrel and Enalapril in AA Diabetics) Comparison of the antihypertensive efficacy and safety of fixed-dose combination therapy with amlodipine/benazepril vs emalapril monotherapy in African Americans with type 2 Diabetes. *Ethn & Dis Vol* (12) 2002.
20. ElAchkar T, Ohmit SE, Grimm R, Bakris G, **Flack JM**. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency. *Diab supp*(51)2: A224, 2002.
21. Hall WD, Clark LT, Wenger NK, Wright JT Jr, Kumanyika SK, Watson K, Horton EW, **Flack JM**, Ferdinand KC, Gavin Jr 3rd, Reed JW, Saunders E, O’Neal W Jr. African-American Lipid and Cardiovascular Council. The metabolic syndrome in African Americans: A review. *Ethn & Dis Vol* 13(4): 414-28, 2003.
22. Artinian, NT, **Flack JM**, Vander Wal JS, Jen KLC, Washington OGM. Depression, stress, and BP control in urban African American women. *Am J Hyper* 17(5,part3) 169A.

Presentations and Abstracts

1. **Flack JM** and Roswell R. “Vitamin D levels in familial hypocalciuric hypercalcemia.” Presented at the American College of Physicians, Oklahoma Society of Internal Medicine State Conference, 1981.

2. **Flack JM.** "A case report of conversion of quinidine resistant atrial fibrillation to normal sinus rhythm with oral flecainide: A promising alternative to the standard therapeutic approaches." Presented at the Regional Meeting of the American College of Physicians, Oklahoma Society of Internal Medicine, October 1986.
3. Ryder KW, Oei TO, **Flack JM**, McDonald CJ, Whang R. "Serum electrolyte abnormalities in patients receiving theophylline." Present at the Indiana University Medical Center, Indianapolis, IN and University of Oklahoma Health Sciences Center, Oklahoma City, OK.
4. Cater NB, **Flack JM.** "Follow-up study of hypercholesterolemic persons identified during mass screening at two shopping centers." Presented at the 29th National Student Research Forum, Galveston, TX, April 6, 1988.
5. **Flack JM**, Wiist W. "Clustering of hypercholesterolemia and hypertension in a large urban Black population." Presented at the First National Cholesterol Conference, Arlington, VA, November 1988.
6. Cater N, **Flack JM.** "Observational study of housestaff/attending physician recognition of hypercholesterolemia in a large teaching hospital." Presented at the First National Cholesterol Conference, Arlington, VA, November 1988.
7. Wiist W, **Flack JM.** "A cholesterol education program in a black church." Presented at the First National Cholesterol Conference, Arlington, VA, November 1988.
8. **Flack JM**, Wiist W. "Report of baseline CHD risk factor prevalence for Northeast Oklahoma City cholesterol education program screenees." Presented at the 116th Annual Meeting of the American Public Health Association, Arlington, VA, November 1988.
9. **Flack JM**, Wiist W. "Relationships between blood pressure, body mass index, and income in black men and women." Presented at the National Conference on High Blood Pressure Control, Lake Buena Vista, FL, May 8, 1989.
10. **Flack JM**, Burke G, Sprafka JM, Grimm RH, Hahn L. "Relationship between blood pressure, lipids and income in black Minnesota heart survey participants." Presented at the Second International Conference on Preventive Cardiology and the 29th Annual Meeting of the American Heart Association Council on Epidemiology. June 18-22, 1989.
11. Mascioli SM, Launer CA, Svendsen KH, Grimm RH, Neaton JD, Elmer PJ, Gonzalez NM, **Flack JM**, Witte L, Bell M, Cox J, Clearman D. "Sodium chloride raises blood pressure in normotensives--The study of sodium and blood pressure." Presented at the 62nd Scientific Sessions of the American Heart Association, New Orleans, LA, November 13-16, 1989.
12. **Flack JM.** "Racial and ethnic modifiers of the sodium-blood pressure response." Presented at the National Heart, Lung, and Blood Institute Salt and Blood Pressure Workshop, Bethesda, MD, Nov. 1-2, 1989.
13. **Flack JM.** For the MIDAS Research Group. "The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)." Presented at the Fifth International Interdisciplinary Conference on Hypertension in Blacks, Long Beach, CA, May 3-7, 1990.
14. **Flack JM**, Wiist W. "The influence of gender and diabetes status on blood pressure, cholesterol and joint blood pressure elevations in adult urban blacks." Presented at the Fifth

- International Interdisciplinary Conference on Hypertension in blacks, Long Beach, CA, May 3-7, 1990.
15. Wiist WH, **Flack JM**. "Dietary intake in African American church attendees." Presented at the Annual Convention of the American Public Health Association, Atlanta, Georgia, November 10-14, 1991.
 16. Sowers JR, Byington R, Furberg CD, Mercuri M, Borhani NQ, Applegie WB, Carr A, Brugger S, **Flack JM**, Schnaper H. "Risk factors associated with atherosclerosis carotid artery thickening in Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)" (Submitted 1991)
 17. Gidding S, Xie X, Manolio T, **Flack JM**, Perkins L, Gardin J. "Relation between smoking and resting cardiac function: The CARDIA Study." Presented at the American Heart Conference in Orlando, Florida, May 21-23, 1992.
 18. **Flack JM**, Grimm RH, Lewis CB, Grandits G, Elmer P, Prineas R, Schoenberger J. "Comparison of response to low dose antihypertensive medication between black and white participants in the treatment of mild hypertension study (TOMHS)." Presented at the Seventh International Interdisciplinary Conference on Hypertension in Blacks, Atlanta, Georgia, May 26-31, 1992.
 19. Elmer PJ, **Flack JM**, Grimm RH, Gonzalez N, Cox J, Herbrandson M, Hillman D, Laing B. "Feasibility of diet sodium reduction in middle-aged Blacks." Presented at the Seventh International Interdisciplinary Conference on Hypertension in Blacks, Atlanta, Georgia, May 26-31, 1992.
 20. Gidding SG, Gardin J, Xie X, **Flack JM**, Manolio T, Sedlacek C. "The prevalence of echocardiographically diagnosed cardiac disease in an asymptomatic population: The CARDIA Study" Presented at the American Heart Conference, New Orleans, Louisiana, November 16-19, 1992.
 21. **Flack JM**, Liu K, Nelson E, Bild D, Hardin M, Hulley S. "Relationship of insulin level to 5-year risk of hypertension in a bi-ethnic cohort of young adults: The CARDIA Study" Presented at the American Heart Conference, Santa Fe, New Mexico, March 17-20, 1993.
 22. **Flack JM**, Yunis C, Keenan J, Sprafka JM, Grimm R, Levin R, Sisson L. "Treatment of low high density lipoprotein (HDL) cholesterol (TOLC) Study" Presented at the 34th Annual Conference on Cardiovascular Disease Epidemiology and Prevention American Heart Association, Tampa FL, March 16-19, 1994.
 23. Prisant LM, Khoury S, **Flack JM**, Carr AA, Sowers JR, Neuwirth R. "Biochemical changes of MIDAS patients according to treatment and race." Presented at the Ninth Interdisciplinary Conference on Hypertension in Blacks, June 22-26, 1994.
 24. Prisant LM, Nichols F, **Flack JM**, Carr AA, Mercuri M, Neuwirth R, Bond G. "Risk factors correlated of carotid intima-media thickness (IMT) of MIDAS patients." Presented at the Ninth Interdisciplinary Conference on Hypertension in Blacks, June 22-26, 1994.
 25. Prisant LM, **Flack JM**, Carr AA, Neuwirth R. "Antihypertensive effects in black and white MIDAS patients" Presented at the Ninth Interdisciplinary Conference on Hypertension in Blacks, June 22-26, 1994.

26. Prisant LM, Nichols F, **Flack JM**, Carr AA, Neuwirth R, Mercuri M, Bond G. "Change in carotid intima-media thickness (IMT) of MIDAS patients." Presented at the Ninth Interdisciplinary Conference on Hypertension in Blacks, June 22-26, 1994.
27. Cohen JD, Edwards A, Cooper R, **Flack JM**, D'Agostino R, Grimm RH, Grundy SM, Kannel WB, Higgins M, Kronmal RA, Hill M, Lee ET. "Workshop on assessing risk for coronary heart disease." Presented for the National Heart, Lung, and Blood Institute, National Institutes of Health, January 19-20, 1999.
28. Weinberger M, Denke M, **Flack JM**, Hunt S, Sacks F, Kotchen T, McCarron D, Svetkey L. Workshop on Sodium and Blood Pressure. "Response to dietary sodium and other nutrients." Presented at the Bethesda Marriott Hotel for the National Heart, Lung, and Blood Institute, National Institutes of Health, January 28-29, 1999.

INVITED PRESENTATIONS (Selected Presentations):

1. African-American International Collaborative Research Scientists Symposium. International Society on Hypertension in Blacks. Zimbabwe, Africa, February 24-28, 1992.
2. Case Western Reserve University, University Hospitals Janice Douglas-David Satcher Address, "Strategies in managing the African American hypertensive with multiple cardiovascular risk factors" Cleveland, Ohio, November 4, 1992.
3. "Salt and high blood pressure: unanswered questions and unquestioned answers." American Heart Association Twentieth Science Writers Forum. January 17-20, 1993.
4. "Is hypertension really different in blacks and the role of genetics in hypertension?" Preventive Cardiology Symposium, Morehouse School of Medicine. March 6, 1993.
5. "The evidence that treatment of hypertension works." Plenary Session VI Eight International Interdisciplinary Conference on Hypertension in Blacks. Yaounde, Cameroon, Africa, April 8, 1993.
6. "Salt and blood pressure: unanswered questions and unquestioned answers." The First Annual Department of Medicine House Staff Research Conference, University of Oklahoma Department of Internal Medicine, April 16, 1993.
7. "Role of Sodium," Plenary Session X, Symposium: Primary Prevention of Hypertension. American Heart Association Annual Scientific Session, Atlanta, Georgia, November 10, 1993.
8. Role of Angiotensin II in Cardiovascular Pathology. "Angiotensin II antagonists in salt-sensitive Hypertension." Satellite Symposium 67th Scientific Sessions American Heart Association, Dallas, Texas, November 13, 1994.
9. Outcomes Management: Conception through Implementation. "Outcomes management: Lessons from TOMHS." Miami Beach, Florida, December 7, 1994.
10. Visiting Professorship in Preventive Medicine "Hypertension and the evolving interface of public health, clinical management and managed care." Houston, TX, March 7-9, 1995.

11. State of the Art Lecture "Systemic hypertension." American College of Cardiology. New Orleans, Louisiana, March 21, 1995.
12. Lectures at AHEC regional hospitals. "Evaluation of renal artery hypertension" North Wilkesboro, NC, April 4, 1995.
13. Oklahoma Heart Research & Education Foundation. "Current trends in therapy, how aggressively should we be treating our patients?" Tulsa, Oklahoma, May 5, 1995.
14. Region III-National Medical Association Annual Conference "Treatment of hypertension: the state of the art." Mobile, Alabama, May 20-21, 1995.
15. American Heart Association Annual Conference. "Epidemiology of heart disease and hypertension in African Americans." Orlando, Florida, November 8, 1997.
16. "Managing Cardiovascular Risk in African-Americans." Presented at the First Conference on Cardiovascular Health: Coming together for the 21st century. San Francisco, CA, February 19, 1998.
17. "Microalbuminuria in minority populations." Presented at National Kidney Foundation (NKF) Consensus Conference on Proteinuria, Nashville, TN, March 25-26, 1998.
18. "Hypertension in blacks." Presented at the World Cardiology Congress, Rio de Janeiro, Brazil, April 30, 1998.
19. "Salt and cardiovascular disease: implications for African Americans." Third Congress on Treatment of Cardiovascular Disease in African Americans, Presented at the American Heart Association, Dallas, Texas, November 10, 1998.
20. "Difficult to treat patient populations and the identification of individual treatment needs." New Therapeutic Goals in Hypertension. Presented at the American Heart Association, Dallas, Texas, November 7, 1998.
21. Keynote speaker, DMC Heart Academy's First Annual Scholarship Banquet, McGregor Memorial Hall, Detroit, MI, November 14, 1998.
22. "Impact of smoking on the CVD-Renal system." Wayne State University Smoking and Interdisciplinary Research Breakfast and Conference, Karmanos Cancer Institute, Detroit, MI, November 19, 1998.
23. "Can the treatment of hypertension prevent sudden death in athletes?" Presented at the John B. Johnson Memorial Lecture and Dinner Gala, Las Vegas, Nevada, August 9, 1999.
24. Regional Differences in Cardiovascular Disease. "Does ethnicity play a role?" Presented at the American Heart Association 72nd Scientific Session, Atlanta, Georgia, November 8, 1999.
25. Hypertension management in special populations and conditions. "African Americans." Presented at the American Heart Association 72nd Scientific Session, Atlanta, Georgia, November 8, 1999.
26. 16th Annual International Society on Hypertension in Blacks (ISHIB). "Aldosterone: "a cardiovascular risk hormone and its importance in hypertension." Las Vegas, Nevada, July 10-15, 2000.

27. 4th Annual Scientific meeting (HFSA). “Racial differences in response to heart failure therapy”. Boca Raton, Florida, Sept 10-13, 2000.
28. National Kidney Disease Education Program. “Screening and Kidney Early Evaluation and Prevention Program” (KEEP). Natcher Conference Center, NIH Campus, Bethesda, MD, March 16, 2001.
29. 2nd International meeting of the International Federation of Kidney Foundation (IFKF). “Association between proteinuria, renal disease and morbidity and mortality. South Los Angeles, CA, October 18-20, 2001
30. Hahemann University Hospital-MCP Hahnemann University School of Medicine, Department of Medicine. “Isolated systolic hypertension (Hypertension in the elderly). Philadelphia, PA, December 12, 2001.
31. Annual International Society on Hypertension in Blacks (ISHIB). “Reversing the cardiovascular disease epidemic among ethnic minority populations: Translating strategies into success. Miami, Florida, June 8-12, 2002.
32. First International Summit on Kidney Disease Prevention Scientific Meeting of the National Kidney Foundation Singapore. “Primary prevention of renal disease and related chronic disease theoretical basis/clinical evidence. Singapore, July 23-27, 2002.
33. American Society of Nephrology, Treatment of hypertension in special populations: “Hypertension and African Americans: are they a special population”? Philadelphia, Pennsylvania, October 30-November 4, 2002.
34. Michigan Department of Health “Cardiovascular drug therapy, which drug for which patient.” Detroit, Michigan, July 14 2003.
35. General Motors (GM) Corporation – 2003 GMAAN All People Meeting, panel discussion on “Hypertension” to GM employees. Warren, Michigan, October 27, 2003.
36. Annual Honor’s Convocation Langston University, Keynote address “A legacy of leadership” to students who have demonstrated leadership and academically excelled. Langston, Oklahoma, April 8, 2004.
37. Henry Clark Stroke Foundation “Hypertension”. Cobo Hall Arena, Detroit, MI May 8, 2004.
38. 19th Annual International Society on Hypertension in Blacks (ISHIB). “Disparities in cardiovascular disease: bridging the great divide”, Detroit, MI June 13-16, 2004.
39. 6th Annual International Fatherhood Conference, “The silent killer of men”. Detroit, MI June 17, 2004.
40. The Michigan Consortium for Minority Health and Academic Development, Keynote Address “Racial and ethnic Disparities: The looking glass into broader societal and health system problems”, Detroit, MI September 29, 2004.
41. WSU School of Medicine, Michigan Department of Community Health. “Health Disparities” Lansing, MI January 18, 2005

42. Henry Ford Hospital Cardiology Grand Rounds. "Benefits of Aldosterone Blockers for Hypertensive Patients". Detroit, MI January 26, 2005.
43. WSU Lecture. "Center for Urban and African American Health and Disparities Related Research". Detroit, MI February 7, 2005
44. WSU Department of Medicine Faculty. "Center for Urban and African American (CUAAH) Grant Initiative". Detroit, MI February 21, 2005.
45. Detroit Medical Society "Hypertension & Lipids", Detroit, MI February 23, 2005.
46. 54th Annual Scientific Session, ACC. Co-Chair "Ethnic Disparity: Optimizing Therapy Across Patient Populations" session, Orlando, FL March 6-9, 2005.
47. WSU College of Nursing Research Day, "Center for Urban and African-American Health (CUAAH): A Multidisciplinary Approach to Complex Research Questions", Detroit, MI March 23, 2005.
48. Boehringer Ingelheim Speaker Series. "Treating the Difficult Hypertension Patient", Southbend, IN April 7, 2005.
49. Boehringer Ingelheim Speaker Series. "Treatment of Hypertension", Fort Wayne IN April 8, 2005.
50. Joint ASH/ISHIB Special Symposium. "Hypertension and Dyslipidemia: Dual Therapy in Cardiovascular Disease Risk Reduction" San Francisco, CA May 14, 2005
51. Henry Ford Wyandotte Grand Rounds. "Hypertension", Wyandotte, MI May 26, 2005.
52. Novartis Speaker Meeting. "Strategies for Managing Hypertension", Kalamazoo, MI May 26, 2005.
53. ISHIB 2005 Scientific Program, "Hypertension Diagnosis, Risk Stratification and Basic Therapeutic Principles" and "Hypertension in African Americans: A State of the Art Lecture" San Juan, Puerto Rico July 13, 2005
54. Henry Ford Wyandotte Hospital – Cardiology Fall Symposium, "Hypertension", Wyandotte, MI September 7, 2005
55. Maya Angelou Research Center, 2005 National Conference on CVD Disparities: Translating Research into Practice, "Unraveling the Tangled Web of Race, Genes, Disease, and Therapeutics" Winston-Salem, NC September 9, 2005